Antivascular agents for non-small-cell lung cancer: Current status and future directions

Expert Opinion on Investigational Drugs

Volumn 18, Issue 11, 2009, Pages 1667-1686

  Amir, Eitan ^a,b   Mandoky, Laszlo ^c   Blackhall, Fiona ^a   Thatcher, Nick ^a   Klepetko, Walter ^d   Ankersmit, Hendrik Jan ^d   Reza Hoda, Mir Ali ^d   Ostoros, Gyula ^e   Dank, Magdolna ^f   Dome, Balazs ^d,e  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Roche Hungary Ltd   (Hungary)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^f SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Angiogenesis; Antivascular drug; Clinical trial; Non small cell lung cancer

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; 3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 3 BENZYLIDENE 6 [(5 TERT BUTYL 1H IMIDAZOL 4 YL)METHYLENE] 2,5 PIPERAZINEDIONE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; AMG 386; AXITINIB; BEVACIZUMAB; BIBF 1120; BMS 690514; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CILENGITIDE; CISPLATIN; DOCETAXEL; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; IMC 1121B; IMC 18F1; IRINOTECAN; KRN 951; LENALIDOMIDE; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MOTESANIB; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; OSI 930; PACLITAXEL; PAZOPANIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VATALANIB; VOLOCIXIMAB; XL 647; XL 999; ZYBERSTAT;

ADJUVANT THERAPY; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC THERAPY; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DYSPNEA; FATIGUE; HEMOPTYSIS; HUMAN; HYPERTENSION; KIDNEY CANCER; KNOWLEDGE; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; OVERALL SURVIVAL; PAIN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 73849135676     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903336050     Document Type: Review

References (138)

1. Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008;44:1345-1389
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
3. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98
4. Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. Expert Rev Anticancer Ther 2003;3:435-442
5. Socinski MA. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms. Clin Cancer Res 2004;10:4210-14s
6. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-420
7. Döme B, Hendrix MJ, Paku S, et al. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007;170:1-15
8. Dome B, Dobos J, Tovari J, et al. Circulating bone marrow-derived endothelial progenitor cells: characterization, mobilization, and therapeutic considerations in malignant disease. Cytometry A 2008;73:186-193
9. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-158
10. Roskoski R Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007;62:179-213
11. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676
12. Escudier B, Pluzanska A, Koralewski P, et al. AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-2111
13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
14. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191
15. Novotny WF, Holmgren E, Griffing S, et al. Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV). Proc Am Soc Clin Oncol 2001;20:abstract 1318
16. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550 (Pubitemid 44917502)
17. Sandler A, Kong G, Strickland D, Johnson HD. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;3:S283
18. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol 2009;27:1227-1234
19. Reck M, von Pawel J, Zatloukal P, et al. First-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous non-small-cell lung cancer (NSCLC) AVAIL (BO17704), a phase III randomized study. J Thorac Oncol 2008;3:S302
20. Patel JD, Hensing TA, Rademaker F, et al. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(Suppl):abstract 8044
21. Lilenbaum R, Raez L, Tseng J, et al. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:511-515
22. SAKK 19/05 trial. Available from: http://clinicaltrials.gov/ct2/show/ NCT00354549 [Last accessed 30 April 2009]
23. INNOVATIONS study. Available from: http://clinicaltrials.gov/ct2/show/ NCT00536640?term= bevacizumab+and+erlotinib+gemcitabin%2C+cisplatin+and+bevacizumab&rank=1 [Last accessed 30 April 2009]
24. Faoro L, Cohen EE, Govindan R, et al. Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(Suppl):abstract 19130
25. Kim ES, Herbst RS, Moon J, et al. S0536: SWOG phase II trial of carboplatin (C), paclitaxel (P), cetuximab (CX) and bevacizumab (B) followed by cetuximab and bevacizumab in advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;3:S266
26. Phase III study showed tarceva in combination with avastin as first-line maintenance therapy improved progression-free survival in advanced lung cancer. Available from: http://www.gene.com/gene/news/press-releases/display.do?method= detail&id=11827 [Last accessed 30 April 2009]
27. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743-4750
28. Hainsworth J, Herbst R. A phase III, multicenter, placebo-controlled, double-blind, randomized, clinical trial to evaluate the efficacy of bevacizumab (Avastin® ) in combination with erlotinib (Tarceva® ) compared with erlotinib alone for treatment of advanced non-small cell lung cancer (NSCLC) after failure of standard first line chemotherapy (BETA). J Thorac Oncol 2008;3:S302
29. Combination chemotherapy, bevacizumab, radiation therapy, and erlotinib in treating patients with stage III NSCLC. Available from: http:// clinicaltrials.gov/ct2/show/NCT00280150 [Last accessed 30 April 2009]
30. BEACON study. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00130780?term=beacon&rank=2 [Last accessed 30 April 2009]
31. Chemotherapy with or without bevacizumab in treating patients with stage IB, stage II, or stage IIIA NSCLC that was removed by surgery. Available from: http://clinicaltrials.gov/ct2/show/NCT00324805?term=ECOG+E1505&rank=1 [Last accessed 30 April 2009]
32. Dansin E, Mezger J, Isla D, et al. Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL). J Clin Oncol 2008;26(Suppl):abstract 8085
33. Bevacizumab summary of product characteristics. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/emea-combined-h582en.pdf [Last accessed 06 October 2009]
34. Hainsworth J, Compton P, Strickland D, Azzoli CG. BRIDGE: an open-label phase ii trial evaluating the safety of bevacizumab (BV) + paclitaxel/ carboplatin (PC) as 1st-line treatment for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;3:S281
35. Akerley WL, Langer CJ, Oh Y, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. J Clin Oncol 2008;26(Suppl):abstract 8043
36. A first-line study of IMC-1121B with paclitaxel and carboplatin in stage IIIB/IV NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/record/ NCT00735696?term=imc-1121b&rank=1 [Last accessed 30 April 2009]
37. Safety study of IMC-18F1 to treat advanced solid tumors in subjects that no longer respond to standard therapy. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00782002?term=imc+18f1&rank=1 [Last accessed 30 April 2009]
38. Massarelli E, Miller VA, Leighl NB, et al. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib-resistant adenocarcinoma of the lung (NSCLA). J Clin Oncol 2007;25:abstract 7627
39. A study of aflibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic NSCLC (VITAL). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00532155?term=aflibercept&cond= lung&rank=2 [Last accessed 30 April 2009]
40. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009;27:2523-2529
41. Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-4277
42. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26:5407-5415
43. Phase III studies show that vandetanib (ZACTIMA) brings clinical benefits to patients with lung cancer. Available from: http://www.astrazeneca.com/media/ latest-press-releases/2008/4215815?itemId=4215815 [Last accessed 30 April 2009]
44. Phase II of Zactima maintenance for locally advanced or metastatic NSCLC following platinum-doublet chemotherapy. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00777179?term=maintenance&cond= nsclc&intr=vandetanib&rank=1 [Last accessed 30 April 2009]
45. Vandetanib, carboplatin, and paclitaxel in treating patients with stage I, stage II, or stage III NSCLC that can be removed by surgery. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00459121?term=neoadjuvant&cond= nsclc&intr=vandetanib&rank=1 [Last accessed 30 April 2009]
46. Radiation therapy (XRT) and ZD6474 in NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00745732?term= radiation&cond=nsclc&intr=vandetanib&rank=2 [Last accessed 30 April 2009]
47. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008;26:1871-1878
48. Goss GD, Laurie S, Shepherd FA, et al. IND. 175: phase I study ofdaily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): a study of the NCIC Clinical Trials Group. J Clin Oncol 2007;25:abstract 7649
49. BR24 Phase II/III study of cediranib in first line NSCLC does not continue into Phase III. Available from: http://www.astrazeneca-us.com/search/? itemId=2289031 [Last accessed 30 April 2009]
50. Gemcitabine and carboplatin with or without AZD2171 as first-line therapy in treating patients with stage IIIB or stage IV NSCLC. Available from: http://clinicaltrials.gov/ct2/show/NCT00326599 [Last accessed 30 April 2009]
51. AZD2171 and pemetrexed disodium in treating patients with relapsed NSCLC. Available from: http://clinicaltrials.gov/ct2/show/NCT00410904?term= cediranib+with+pemetrexed&rank=2 [Last accessed 30 April 2009]
52. Schiller JH, Larson T, Ou SI, et al. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial. J Clin Oncol 2007;25:abstract 7507
53. A study of AG-013736 (Axitinib) or bevacizumab (Avastin) in combination with paclitaxel and carboplatin in patients with advanced lung cancer. Available from: http://clinicaltrials.gov/show/NCT00600821 [Last accessed 30 April 2009]
54. Trial of AG-013736, cisplatin, and gemcitabine for patients with squamous NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00735904?cond= nsclc&intr=axitinib&rank=1 [Last accessed 30 April 2009]
55. Gatzemeier U, Blumenschein G, Fosella F, et al. A Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 2006;24:abstract 7002
56. Liu B, Barrett T, Choyke P, et al. A phase II study of BAY 43-9006 (Sorafenib) in patients with relapsed non-small cell lung cancer (NSCLC).J Clin Oncol 2006;24:abstract 17119
57. Phase III trial of nexavar in patients with NSCLC. Available from: http://www.onyxgrant.com/view.cfm/392/Bayer-and-Onyx-Provide-Update-on-Phase-3- Trial-of-Nexavar-in-Patients-With-Non-Small-Cell-Lung-Cancer-Onyx- Pharmaceuticals [Last accessed 30 April 2009]
58. Bayer and Onyx provide update on Phase III Trial of Nexavar® in patients with NSCLC. Available from: http://www.viva.vita.bayerhealthcare.com/ index.php?id=36&tx-ttnews[tt-news]=12229&cHash=1e3cf6aec3 [Last accessed 30 April 2009]
59. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007;13:2684-2691
60. Sorafenib and thoracic radiation for patients with NSCLC. Available from: www.clinicaltrials.gov/ct2/show/NCT00543335?cond=nsclc&intr= sorafenib&rank=14 [Last accessed 30 April 2009]
61. Socinski MA, Samant M, Strickland D, Kozloff M. Sabre-l: a randomized phase ii trial evaluating the safety and efficacy of combining sunitinib (S) with bevacizumab (BV) + paclitaxel/carboplatin (PC) as first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;3:S281
62. Blais N, Page RD, Hainsworth JD, et al. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol 2008;3:S283
63. Brahmer JR, Govindan R, Novello S, et al. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25:S7542
64. Govindan R, Blumenschein G, Groen HJM, et al. Sunitinib (SU) plus erlotinib (E) for metastatic non-small cell lung cancer (NSCLC): a novel VEGFR-EGFR combination treatment strategy. J Thorac Oncol 2008;3:S289
65. Blumenschein G Jr, Sandler A, O'Rourke T, et al. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2006;24(18 Suppl):abstract 7119
66. A Phase II trial of AMG 706 or bevacizumab in combination with chemo for advanced NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00369070?term=motesanib&cond=nsclc&rank=2 [Last accessed 30 April 2009]
67. Independent Data Monitoring Committee recommends resuming enrollment of non-squamous NSCLC patients in the Motesanib MONET1 trial. Available from: http://www.amgen.com/media/media-pr-detail.jsp?year=2009&releaseID=1255738 [Last accessed 30 April 2009]
68. Safety and efficacy study of a new chemotherapy agent to treat NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00160043?term= vatalanib&cond=nsclc&rank=1 [Last accessed 30 April 2009]
69. Gauler TC, Besse B, Meric JB, et al. Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(Suppl 18s):7541
70. Altorki NK, Heymach JV, Guarino MJ, et al. Phase II study of pazopanib (GW786034) given preoperatively in stage I-II NSCLC: a proof-of-concept study. J Thorac Oncol 2008;3:S263
71. Adjuvant pazopanib in stage I NSCLC. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00775307?cond=nsclc&intr=pazopanib&rank= 3 [Last accessed 30 April 2009]
72. Monotherapy pazopanib in subjects with advanced NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00549328?cond=nsclc&intr= pazopanib&rank=2 [Last accessed 30 April 2009]
73. Lee CP, Attard G, Poupard L, et al. A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2005;23:205s
74. Von Pawel J, Kaiser R, Eschbach C, et al. A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:abstract 7635
75. LUME-Lung 1: BIBF 1120 plus docetaxel as compared to placebo plus docetaxel in second line NSCLC. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00805194?term=bibf+1120&cond=nsclc&rank=1 [Last accessed 30 April 2009]
76. Lume Lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in second line nonsquamous NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00806819?term=bibf+1120&cond= nsclc&rank=2 [Last accessed 30 April 2009]
77. Study of ABT-869 in subjects with advanced NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00517790?term=NCT00517790&rank=1 [Last accessed 30 April 2009]
78. Study of carboplatin/paclitaxel in combination with ABT-869 in subjects with advanced or metastatic NSCLC. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00716534?cond=nsclc&intr=abt-869&rank=2 [Last accessed 30 April 2009]
79. A Phase I study of BMS-690514 in combination with paclitaxel and carboplatin. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00420186? term=BMS-690514&rank=3 [Last accessed 30 April 2009]
80. A comparison between BMS-690514 and erlotinib in patients who were previously treated for NSCLC. Available from: http://clinicaltrials.gov/ct2/ show/NCT00743938 [Last accessed 30 April 2009]
81. de La Motte Rouge T, Galluzzi L, Olaussen KA, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in nonsmall cell lung cancer cells resistant to erlotinib. Cancer Res 2007;67:6253-6262
82. Rosenfeld-Franklin M, Silva S, Pirritt C, et al. Antitumor efficacy of OSI-930 and the molecular targeted agent erlotinib in preclinical xenograft models. J Clin Oncol 2008;26(15 Suppl):14596
83. Lal R, Camidge DR, George S, et al. A phase I, dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930, an oral tyrosine kinase inhibitor (TKI), in patients (pts) with advanced solid tumors. J Clin Oncol 2008;26(15 Suppl):3553
84. Phase I study of OSI-930 and erlotinib in cancer tumors. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00603356?term=osi-930&rank=2 [Last accessed 30 April 2009]
85. Nakachi I, Naoki K, Soejima K, et al. Enhanced growth inhibition of human NSCLC cell resistant to gefitinib (ZD1839) by a dual tyrosine kinase inhibitor of EGFR/VEGFR2 (AEE788) in combination with a mTOR inhibitor (RAD001). Proc Am Assoc Cancer Res 2006;47:abstract 5081
86. Baselga J, Rojo F, Dumez H, et al. Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen. J Clin Oncol 2005;23:abstract 3028
87. Martinelli E, Takimoto C, Van Oosterom A, et al. AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: preliminary phase 1 results. J Clin Oncol 2005;23:abstract 3039
88. Study of oral AEE788 in adults with advanced cancer. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00118456?term=aee788&rank=1 [Last accessed 30 April 2009]
89. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol 2007;8:15-27
90. Wakelee H, Adjei AA, Halsey J, et al. A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies. J Clin Oncol 2006;24:3044
91. Pakkala S, Ramalingam SS. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer 2009;10:S17-23
92. Study of XL647 in subjects with NSCLC who have progressed after responding to treatment with gefitinib or erlotinib. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00522145?term=xl647&rank=4 [Last accessed 30 April 2009]
93. March RJ, Mirtsching B, Modi S, et al. A phase II study of XL999 in patients (pts) with NSCLC. J Clin Oncol 2007;25(18 Suppl):abstract 18112
94. Cohen RB, Langer CJ, Simon GR, et al. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol 2007;60:81-89
95. Phase I and II data of AV-951. Available from: http://www.aveopharma.com/ content/rd/products/av-951.jsp [Last accessed 30 April 2009]
96. An open-label study of QD oral administration of AV-951 in subjects with NSCLC. Available from: http://clinicaltrials.gov/ct2/show/record/NCT00826878 [Last accessed 30 April 2009]
97. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085
98. Miller AA, Case D, Atkins J, Giguere J. Phase II study of carboplatin, irinotecan and thalidomide in patients with advanced nonsmall cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004;22:7132
99. Flora DB, Kleykamp B, Knapp M, et al. A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced nonsmall cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2004;22:7258
100. Docetaxel and thalidomide as second-line therapy in treating patients with stage III or stage IV NSCLC. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT00114192?cond=nsclc&intr=thalidomide&rank=2 [Last accessed 30 April 2009]
101. Carboplatin, gemcitabine, and thalidomide in treating patients who are undergoing surgery for stage II or stage III NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00281827?cond=nsclc&intr= thalidomide&rank=4 [Last accessed 30 April 2009]
102. Carboplatin, paclitaxel, and radiation therapy with or without thalidomide in treating patients with stage III NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00004859?cond=nsclc&intr= thalidomide&rank=1 [Last accessed 30 April 2009]
103. Sharma RA, Steward WP, Daines CA, et al. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 2006;42:2318-2325
104. A study to evaluate the single-agent lenalidomide in subjects with recurrent NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00179686?term=lenalidomide&cond=nsclc&rank=1 [Last accessed 30 April 2009]
105. Leighl NB, Paz-Ares L, Douillard JY, et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005;23:2831-2839
106. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 2003;39:917-926
107. Undevia SD, Janisch L, Stadler WM, et al. A phase I and pharmacokinetic study of continuous infusion EMD 121974 (EMD), an antiangiogenic alphavbeta3 and alphavbeta5 integrin antagonist, in patients with advanced solid malignancy. J Clin Oncol 2006;24:abstract 3052
108. Cilengitide and cetuximab in combination with platinum-based chemotherapy as first-line treatment for subjects with advanced NSCLC (CERTO). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00842712?term= cilengitide+nsclc&rank=1 [Last accessed 06 October 2009]
109. Ricart AD, Tolcher AW, Liu G, et al. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin Cancer Res 2008;14:7924-7929
110. A Phase Ib study with volociximab in combination with carboplatin and paclitaxel in first-line, advanced NSCLC. Available from: http://www. clinicaltrials.gov/ct2/show/NCT00654758?term=volociximab&rank=1 [Last accessed 30 April 2009]
111. A Phase Ib study with volociximab in combination with carboplatin, paclitaxel, and bevacizumab in first-line, advanced NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00666692?sterm=volociximab&rank=3 [Last accessed 30 April 2009]
112. Volociximab and erlotinib in treating patients with stage III or stage IV NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00278187?term= volociximab&rank=5 [Last accessed 30 April 2009]
113. Herbst RS, Madden TL, Tran HT, et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 2002;20:4440-4447
114. Rosen LS, Hong D, Chap L, et al. First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors. J Clin Oncol 2007;25:abstract 3522
115. Mita AC, Wang D, Takimoto CH, et al. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. J Clin Oncol 2007;25:abstract 14033
116. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165
117. Patterson DM, Rustin GJ. Vascular damaging agents. Clin Oncol (R Coll Radiol) 2007;19:443-456
118. McKeage MJ, Von Pawel J, Reck M, et al. Randomized phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-2012
119. ASA404 or placebo in combination with paclitaxel and carboplatin as first-line treatment for stage IIIb/IV NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00662597?cond=NSCLC&intr= ASA404&rank=2 [Last accessed 30 April 2009]
120. A study of ASA404 or placebo in combination with docetaxel in second-line treatment for (stage IIIb/IV) NSCLC (ATTRACT-2). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00738387?cond=NSCLC&intr= ASA404&rank=1 [Last accessed 30 April 2009]
121. A study to assess the effectiveness of the combination of carboplatin, paclitaxel, bevacizumab and combretastatin (CA4P) in patients with chemotherapy naïve lung cancer. Available from: http://www.clinicaltrials.gov/ct2/show/ record/NCT00653939?cond=nsclc&intr=ca4p&rank=1 [Last accessed 30 April 2009]
122. Mita C, Yee LK, Papadopoulos KP, et al. Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. J Clin Oncol 2008;26:3525
123. Phase I/II study of vascular disrupting agent NPI-2358 + docetaxel in patients with advanced NSCLC. Available from: http://www.clinicaltrials.gov/ct2/ show/record/NCT00630110?term=NPI-2358&rank=1 [Last accessed 30 April 2009]
124. Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006;12:2834-2840
125. Fox E, Maris JM, Widemann BC, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12:4882-4887
126. Yee KW, Hagey A, Verstovsek S, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005;11:6615-6624
127. A Phase II study evaluating ABT-751 in combination with Alimta in advanced NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00297089?cond=nsclc&intr=abt+751&rank=1 [Last accessed 30 April 2009]
128. A Phase II study evaluating ABT-751 in combination with Taxotere in advanced NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00354562?cond=nsclc&intr=abt+751&rank=2 [Last accessed 30 April 2009]
129. A study of ABT-751 in patients with NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00073151?cond=nsclc&intr= abt+751&rank=3 [Last accessed 30 April 2009]
130. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 (Pubitemid 30099779)
131. Dome B, Timar J, Ladanyi A, et al. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: from biology to therapy. Crit Rev Oncol Hematol 2009;69:108-124
132. Lower dose chemotherapy given more frequent with Avastin to treat advanced non-squamous NSCLC. Available from: http://www.clinicaltrials.gov/ct2/ show/NCT00655850?term=NCT00655850&rank=1 [Last accessed 30 April 2009]
133. Paclitaxel and carboplatin with or without nitroglycerin in treating patients with previously untreated stage III or stage IV NSCLC. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00616031?term=NCT00616031&rank=1 [Last accessed 30 April 2009]
134. Malignant pleural effusion with ZD6474. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00402896?term=NCT00402896&rank=1 [Last accessed 30 April 2009]
135. Vandetanib and bevacizumab in treating patients with advanced solid tumors or lymphoma. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00734890?term=NCT00734890&rank=1 [Last accessed 30 April 2009]
136. Impact of Endostar combined with chemotherapy on the angiogenesis of advanced NSCLC. Available from: http://www.clinicaltrials.gov/ct2/results?term= NCT00657423 [Last accessed 30 April 2009]
137. Pathak AP, Hochfeld WE, Goodman SL, Pepper MS. Circulating and imaging markers for angiogenesis. Angiogenesis 2008;11:321-335
138. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49(Suppl 2):113-28S